Skye Bioscience to Participate in Upcoming Investment Conferences
Skye Bioscience (NASDAQ: SKYE) will participate in three investor conferences in early December 2025, offering investor access via scheduled 1x1 meetings and two public fireside chats. Key events and dates include:
- Citi Global Healthcare Conference (Miami) — 1x1 meetings on Dec. 2, 2025
- Evercore Annual Healthcare Conference (Coral Gables) — Fireside chat on Dec. 3, 2025 at 12:55 pm ET plus 1x1 meetings
- Piper Sandler Annual Healthcare Conference (New York) — Fireside chat on Dec. 4, 2025 at 11:30 am ET plus 1x1 meetings
Available webcasts will be accessible on Skye's investor website.
Skye Bioscience (NASDAQ: SKYE) parteciperà a tre conferenze per investitori all'inizio di dicembre 2025, offrendo accesso agli investitori tramite incontri 1x1 programmati e due conversazioni pubbliche informali. Gli eventi chiave e le date includono:
- Citi Global Healthcare Conference (Miami) — incontri 1x1 il 2 dicembre 2025
- Evercore Annual Healthcare Conference (Coral Gables) — conversazione informale il 3 dicembre 2025 alle 12:55 p.m. ET più incontri 1x1
- Piper Sandler Annual Healthcare Conference (New York) — conversazione informale il 4 dicembre 2025 alle 11:30 a.m. ET più incontri 1x1
Le webcast disponibili saranno accessibili sul sito degli investitori di Skye.
Skye Bioscience (NASDAQ: SKYE) participará en tres conferencias para inversores a principios de diciembre de 2025, ofreciendo acceso a inversores a través de reuniones 1x1 programadas y dos charlas públicas. Los eventos clave y las fechas son:
- Citi Global Healthcare Conference (Miami) — reuniones 1x1 el 2 de diciembre de 2025
- Evercore Annual Healthcare Conference (Coral Gables) — charla en el diálogo informal el 3 de diciembre de 2025 a las 12:55 p.m. ET más reuniones 1x1
- Piper Sandler Annual Healthcare Conference (New York) — charla en el diálogo informal el 4 de diciembre de 2025 a las 11:30 a.m. ET más reuniones 1x1
Las transmisiones web disponibles estarán disponibles en el sitio de inversores de Skye.
Skye Bioscience(NASDAQ: SKYE)는 2025년 12월 초에 세 개의 투자자 컨퍼런스에 참여하며, 예정된 1대1 미팅과 두 번의 공개 핫토크를 통해 투자자 접근을 제공합니다. 주요 행사 및 일정은 다음과 같습니다:
- Citi Global Healthcare Conference (Miami) — 2025년 12월 2일에 1대1 미팅
- Evercore Annual Healthcare Conference (Coral Gables) — 2025년 12월 3일 12:55pm ET의 핫토크 + 1대1 미팅
- Piper Sandler Annual Healthcare Conference (New York) — 2025년 12월 4일 11:30am ET의 핫토크 + 1대1 미팅
가능한 웹캐스트는 Skye의 투자자 웹사이트에서 접속할 수 있습니다.
Skye Bioscience (NASDAQ : SKYE) participera à trois conférences pour investisseurs au début de décembre 2025, en offrant l'accès aux investisseurs via des réunions 1x1 prévues et deux conversations publiques. Les événements clés et les dates sont les suivants :
- Conférence mondiale des soins de santé Citi (Miami) — réunions 1x1 le 2 décembre 2025
- Evercore Annual Healthcare Conference (Coral Gables) — discussion informelle le 3 décembre 2025 à 12h55 HE plus des réunions 1x1
- Piper Sandler Annual Healthcare Conference (New York) — discussion informelle le 4 décembre 2025 à 11h30 HE plus des réunions 1x1
Les webcasts disponibles seront accessibles sur le site des investisseurs de Skye.
Skye Bioscience (NASDAQ: SKYE) wird Anfang Dezember 2025 an drei Investorenkonferenzen teilnehmen und Investoren Zugang über geplante 1x1-Gespräche sowie zwei öffentliche Fireside Chats ermöglichen. Wichtige Veranstaltungen und Termine umfassen:
- Citi Global Healthcare Conference (Miami) — 1x1-Gespräche am 2. Dezember 2025
- Evercore Annual Healthcare Conference (Coral Gables) — Fireside-Chat am 3. Dezember 2025 um 12:55 Uhr ET plus 1x1-Gespräche
- Piper Sandler Annual Healthcare Conference (New York) — Fireside-Chat am 4. Dezember 2025 um 11:30 Uhr ET plus 1x1-Gespräche
Verfügbare Webcasts werden auf der Skye-Investorenseite zugänglich sein.
Skye Bioscience (بورصة ناسداك: SKYE) ستشارك في ثلاث مؤتمرات للمستثمرين في أوائل ديسمبر 2025، مع منح المستثمرين إمكانية الوصول من خلال اجتماعات 1x1 مجدولة واثنين من المحادثات العامة Fireside Chats. تشمل الفعاليات الرئيسية والتواريخ:
- Citi Global Healthcare Conference (Miami) — اجتماعات 1x1 في 2 ديسمبر 2025
- Evercore Annual Healthcare Conference (Coral Gables) — محادثة Fireside في 3 ديسمبر 2025 الساعة 12:55 مساءً بتوقيت شرق الولايات المتحدة بالإضافة إلى اجتماعات 1x1
- Piper Sandler Annual Healthcare Conference (New York) — محادثة Fireside في 4 ديسمبر 2025 الساعة 11:30 صباحاً بتوقيت شرق الولايات المتحدة بالإضافة إلى اجتماعات 1x1
ستكون البثوث المباشرة المتاحة متاحة على الموقع الاستثماري لشركة Skye.
- None.
- None.
San Diego, California--(Newsfile Corp. - November 24, 2025) - Skye Bioscience, Inc. (NASDAQ: SKYE) ("Skye"), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will participate in the following upcoming investment conferences:
Citi Global Healthcare Conference (Miami)
1x1 meetings: Dec. 2Evercore Annual Healthcare Conference (Coral Gables)
Fireside Chat: Dec. 3, 12:55 pm ET
1x1 meetingsPiper Sandler Annual Healthcare Conference (New York)
Fireside Chat: Dec. 4, 11:30 am ET
1x1 meetings
Available webcasts will be accessible on Skye's website.
About Skye Bioscience
Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of potential first-in-class therapeutics with potential clinical and commercial differentiation. Skye is conducting a Phase 2a clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: www.skyebioscience.com. Connect with us on X and LinkedIn.
CONTACTS
Investor & Media Relations
ir@skyebioscience.com
(858) 410-0266
LifeSci Advisors, Mike Moyer
mmoyer@lifesciadvisors.com
(617) 308-4306

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/275680